Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK, safety, tolerability, and PD of JNT-517 in healthy Japanese adult males
jRCT2071260047Phase 1Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of repinatrabit in None (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Plasma concentrations of JNT-517 and Pharmacokinetic parameters of JNT-517. Started Jul 2026; status: recruiting.
02
Drugs
repinatrabit
Beyond the preview
Go deeper on jRCT2071260047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260047.